Research & Markets: Par Pharmaceutical Boosted its Position in the US Market Through the Purchase of a Number of Drugs from Teva and IVAX

Business Wire, May 28, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49747) has announced the addition of the Espicom Business Intelligence Ltd report: "Par Pharmaceutical Generics Company Intelligence Report" to their offering.

Our generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Par Pharmaceutical was founded in New York in 1978. Many products are licensed-in from other generic manufacturers, such as Genpharm or Spectrum, or originator companies. Par has concluded a number of authorised generic agreements with originators, most recently with AstraZeneca for metoprolol ER.

Par's in-house manufacturing capabilities revolve principally around Kali Laboratories, a company acquired in 2004. Both companies hold a number of ANDAs under their own name. The most recent drug to be approved is ondansetron, a version of Merck's Zofran.

The company boosted its position in the US market in 2006, through the purchase of a number of drugs from Teva and IVAX. This was mandated by the FTC as a condition of the merger between the latter two companies.

Topics Covered
Executive Summary

Introduction
Kali Laboratories

Products
Teva/IVAX Drugs Divested to Par Pharmaceutical Companies
Par Pharmaceutical ANDA Approvals, 2002-06
Kali Laboratories ANDA Approvals, 2004-06
Recent Product Approvals
Ondansetron
Pravastatin.
Companies gain meloxicam approvals
Orchid gains cephalexin ANDA approval
Amlodipine besylate tablets (tentative)
Tranylcypromine sulphate tablets
Miralax generic

Financial results
Par Pharmaceutical Financial Results 2001-05 (US$000s)
Generic/Branded Revenues & Operating Income, 2003-05 (US$000s)
Par Sales of Selected Generic Products, 2003-05 (US$000s)

Major Developments
Mergers, acquisitions and agreements
AstraZeneca/Par enter agreement for generic version of Toprol-XL
Spectrum Pharmaceuticals
Sumatriptan injection
Par divests FineTech
Bradley and Par enter licensing agreement for Adoxa
MN Pharmaceuticals
Orchid Chemicals & Pharmaceuticals
Litigation
Reliant files patent infringement lawsuit against Par over Rythmol
Unimed, Watson, Paddock and Par enter settlement agreements regarding
AndroGel litigation

Contact Details

For more information, visit http://www.researchandmarkets.com/reports/c49747